Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS-3: Tocilizumab + Endovascular Treatment in Acute Posterior Circulation Stroke
NCT07509645Phase 3Recruiting
- Sponsor
- Capital Medical University
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in ischemic stroke, sponsored by Capital Medical University. Started Apr 2026; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07509645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509645.